Plus Therapeutics

Plus Therapeutics Net Margin

Delisted·Sep 22, 2026

The Net Profit Margin of Plus Therapeutics (PSTV) as of Nov 2, 2026 is -429.43 %. In the previous year, Net Profit Margin was -222.84 % — a change of 92.71% (lower).

Net Margin

-429.43 %

YoY

92.71%

Last updated:

Net Profit Margin of Plus Therapeutics is 2025 -429.43 % . Net Profit Margin of Plus Therapeutics was 2024 -222.84 % . It decreases by 92.71% lower compared to the previous year.

For Plus Therapeutics, the net margin of -429.4% is up versus -2,719.8% a few years ago.

The Plus Therapeutics Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2017
-353.86 USD
Jan 1, 2018
-423.53 USD
Jan 1, 2019
-155.57 USD
Jan 1, 2020
-2,719.80 USD
Jan 1, 2022
-9,051.34 USD
Jan 1, 2023
-271.04 USD
Jan 1, 2024
-222.84 USD
Jan 1, 2025
-429.43 USD
The Plus Therapeutics Net Margin history
YEARNet MarginYoY
-429.43 %+92.71%
-222.84 %-17.78%
-271.04 %-97.01%
-9,051.34 %+232.79%
-2,719.80 %+1,648.25%
-155.57 %-63.27%
-423.53 %+19.69%
-353.86 %+82.66%
-193.73 %+20.50%
-160.77 %-67.31%
-491.81 %+22,813.85%
-2.15 %-3.58%
-2.23 %-31.43%
-3.25 %+25.48%
-2.59 %+64.15%
-1.58 %-64.04%
-4.38 %-7.53%
-4.74 %+47.65%
-3.21 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Plus Therapeutics Stock analysis

What does Plus Therapeutics do? Plus Therapeutics, Inc. generates revenue through the development and commercialization of innovative cancer treatments, primarily focusing on reformulating existing chemotherapeutics using its nanotechnology platform. The company’s lead product, DocePLUS, is an albumin-stabilized PEGylated liposomal formulation of docetaxel designed for small cell lung cancer (SCLC) treatment, while DoxoPLUS is a generic PEGylated liposomal formulation of doxorubicin targeting breast cancer, ovarian cancer, multiple myeloma, and Kaposi’s sarcoma. These products are developed to address unmet medical needs in oncology, with a focus on improving efficacy and reducing side effects for patients and healthcare providers. The company targets healthcare providers and oncology specialists who prescribe chemotherapy regimens, as well as patients with specific cancer types requiring advanced treatment options. By leveraging its nanotechnology platform to enhance existing chemotherapeutics, Plus Therapeutics aims to provide cost-effective alternatives to branded oncology drugs, particularly in the generic oncology drug segment. The firm’s strategy centers on developing treatments for rare and complex diseases where current therapies fall short, aligning with its clinical-stage focus on cancer and rare diseases. Plus Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Plus Therapeutics stock

Net Profit Margin of Plus Therapeutics is -429.43 % in 2025.

Net Profit Margin of Plus Therapeutics changed from -222.84 % to -429.43 %, representing a 92.71% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Plus Therapeutics since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Plus Therapeutics with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Plus Therapeutics

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Plus Therapeutics